CFTR and cystic fibrosis: This gap, coupled with lack of potential bicarbonate-correcting therapy for people with CF ineligible for CFTR modulator therapies (because of genotype or medical contraindication), has driven us to seek ways to improve intestinal bicarbonate secretion independent of CFTR.